In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are reported.(1,2,3)
2-weekly docetaxel: issues for clinical practice / Massari, F., Maines, F., Bria, E., Galligioni, E., Caffo, O., Tortora, G.. - In: CANCER BIOLOGY & THERAPY. - ISSN 1538-4047. - 16:1(2015), pp. 17-18. [10.4161/15384047.2014.987534]
2-weekly docetaxel: issues for clinical practice
Maines, F.;Caffo, O.;
2015-01-01
Abstract
In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are reported.(1,2,3)File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
2-weekly docetaxel issues for clinical practice.pdf
Solo gestori archivio
Tipologia:
Versione editoriale (Publisher’s layout)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
313.02 kB
Formato
Adobe PDF
|
313.02 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
